Launched on February 19, 2026, lenacapavir the injectable HIV prevention drug given just twice a year is no longer just a promise in Zimbabwe. Six months on, real numbers from the field back up what looked like a breakthrough at the time, and it fits into two decades of steady progress against the epidemic.
Health Minister Douglas Mombeshora officially launched the program in Harare and Epworth back in February, calling it an important step in the country’s HIV response and a commitment to ending AIDS as a public health threat. Developed by US drugmaker Gilead Sciences and approved locally in November 2025, lenacapavir is given as a simple subcutaneous injection, twice a year. Clinical trials put its effectiveness at close to 100 percent for people at risk — good enough that WHO Director-General Tedros Adhanom Ghebreyesus called it the next best thing to an HIV vaccine.
By becoming one of the first countries anywhere to roll it out nationally, Zimbabwe was building on a track record it started in 2022, when it became the first African country to approve long-acting injectable cabotegravir.
By May 7, 2026, 1,478 people had already started on lenacapavir in the country — 67 percent women, 33 percent men. One number stands out: about 42 percent of users switched over from another prevention method, either daily oral PrEP or injectable cabotegravir, which tells you the new drug is winning over people already in the system, not just pulling in newcomers. Idah Moyo, the health ministry’s HIV Prevention Officer, said lenacapavir is strengthening the national program simply by giving patients more options to choose from.
On the ground, the stories back that up. Emily Chikoto, 29, from Bulawayo, had tried nearly everything available in Zimbabwe — daily pills, the monthly vaginal ring, injectable cabotegravir — before switching to lenacapavir. « For me, this is the best option so far, » she said. « I only think about it twice a year, and then I continue with my life. »
The scale of the program has grown since February too. The initial target was 46,000 high-risk people across 24 sites; the US has since committed to supporting access for roughly 271,000 people over the next three years — a sharp upward revision that reflects the program picking up speed. Funding runs jointly through PEPFAR and the Global Fund to Fight AIDS, Tuberculosis and Malaria, which has already put roughly $1.8 billion into Zimbabwe since 2003.
Data presented in July 2026 at the 26th International AIDS Conference in Rio de Janeiro puts Zimbabwe’s rollout in a much bigger picture. It’s one of nine African countries now offering lenacapavir, alongside Eswatini, Kenya, Lesotho, Mozambique, Nigeria, South Africa, Uganda and Zambia. Across those nine countries, roughly 191,620 doses had been delivered by mid-2026, with nearly 66,000 people newly started on the drug across more than 900 sites, and over 10,000 healthcare workers trained to administer it. The regional target is now at least three million people covered by the end of 2028. The one catch experts flagged: demand is already outpacing supply in some of the participating countries.
None of this happened in a vacuum. Zimbabwe has already hit the UNAIDS 95-95-95 targets — 95 percent of people living with HIV know their status, 95 percent of those diagnosed are on treatment, and 95 percent of those on treatment have suppressed viral loads. HIV prevalence in the country has dropped from around 34 percent in the early 2000s to roughly 12 percent today, out of a population of about 1.3 million people currently living with the virus.
Six months in, lenacapavir in Zimbabwe has moved past being a political announcement. The numbers on the ground, the patient stories, and a funding commitment that’s already been revised upward all point to something real. If the rollout keeps expanding and the supply issues seen elsewhere in the region get sorted out, this drug could end up being one of the tools that finally gets Zimbabwe to where it’s been working toward for two decades: ending AIDS as a threat to public health.
